Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Dinutuximab + Irinotecan + Sargramostim + Temozolomide + TGF-beta-imprinted NK cells |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Dinutuximab | Unituxin | MOAB Ch14.18 | GD2 Antibody 6 | Unituxin (dinutuximab) is a monoclonal antibody that targets B4GALNT1 (GD2) and increases antibody-dependent and complement-dependent cytotoxicity against GD2-expressing tumor cells (PMID: 26917818). Unituxin (dinutuximab) is FDA approved for pediatric high-risk neuroblastoma (FDA.gov). |
| Irinotecan | Camptosar | CPT-11 | TOPO1 inhibitor 11 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
| Sargramostim | Leukine | GM-CSF|Prokine | ||
| TGF-beta-imprinted NK cells | TGF-beta-imprinted NK cells are natural killer cells that have been imprinted by TGF-beta during activation and expansion, which potentially leads to increased secretion of pro-inflammatory cytokines and enhanced antitumor immune response (NCI Drug Dictionary). | |||
| Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06450041 | Phase II | Dinutuximab + Irinotecan + Sargramostim + Temozolomide + TGF-beta-imprinted NK cells | NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial | Recruiting | USA | 0 |